论文部分内容阅读
目的 :探讨不同治疗策略用于晚期肺癌患者的临床疗效。方法 :回顾性分析我院收治没有手术指征的晚期肺癌及术后复发的患者,随机分成全剂量化疗、姑息化疗及对症支持三组,给予不同的治疗策略,评估治疗期间的不良反应、生活质量和临床疗效,对生存期进行随访。结果 :针对血清肿瘤标志物水平,全剂量化疗组术后下降明显,姑息化疗组略微下降,而对症支持组基本无降低,甚至有部分升高。在不良反应和生活质量方面,全剂量化疗组副作用大,远期生存时间最差,姑息化疗组影响不大,明显提升生存时间,对症支持组生存时间次之。结论 :对于晚期无手术指征肺癌患者及术后复发患者,姑息化疗临床疗效更优,临床上应尽量选用该治疗方案。
Objective: To investigate the clinical effects of different treatment strategies in patients with advanced lung cancer. Methods: A retrospective analysis of our hospital for patients with advanced lung cancer without surgical indications and postoperative recurrence was randomly divided into three groups: full-dose chemotherapy, palliative chemotherapy and symptomatic support. Different treatment strategies were given to evaluate the adverse reactions during treatment and life Quality and clinical efficacy, follow-up of survival. Results: According to the level of serum tumor markers, the full-dose chemotherapy group decreased significantly after surgery and slightly decreased in the palliative chemotherapy group, with no significant decrease or even some increase in the symptomatic support group. In adverse reactions and quality of life, the full-dose chemotherapy group had a large side effect, the long-term survival time was the worst, the impact of palliative chemotherapy group was not significant, and the survival time was obviously improved. The survival time of the symptomatic support group was second. Conclusions: Palliative chemotherapy is more effective in patients with advanced lung cancer without surgical indications and patients with recurrent postoperative recurrence. Clinically, this regimen should be used as far as possible.